Roche’s Gazyva/Gazyvaro Shows Superiority To Standard Therapy In Phase III Lupus Nephritis Study
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis has yielded positive topline results.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1233676424-c891b2d7f89446f58b98d3b7d10d2ff3.jpg "Campaign Promises and the Economy")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2076671053-ff0e800c89684fabb96eb46d32650e55.jpg "Why and How Student Loan Creditors Can Garnish Your Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-510752465-10cdb9eac0884220ae04232d2950ca87.jpg "This Is the Perfect Place for Your Second Home Abroad—And It Might Not Be Where You Think")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1567505009-09f8705bfdcd40aaa9797052677728ba.jpg "Using the Coppock Curve to Generate Trade Signals")